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Abstract
Background: Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine involved in cystitis and a non-
cognate ligand of the chemokine receptor CXCR4 in vitro. We studied whether CXCR4-MIF associations occur in rat bladder
and the effect of experimental cystitis.
Methods and Findings: Twenty male rats received saline or cyclophosphamide (40 mg/kg; i.p.; every 3
rd day) to induce
persistent cystitis. After eight days, urine was collected and bladders excised under anesthesia. Bladder CXCR4 and CXCR4-
MIF co-localization were examined with immunhistochemistry. ELISA determined MIF and stromal derived factor-1 (SDF-1;
cognate ligand for CXCR4) levels. Bladder CXCR4 expression (real-time RTC-PCR) and protein levels (Western blotting) were
examined. Co-immunoprecipitations studied MIF-CXCR4 associations.Urothelial basal and intermediate (but not superficial)
cells in saline-treated rats contained CXCR4, co-localized with MIF. Cyclophosphamide treatment caused: 1) significant
redistribution of CXCR4 immunostaining to all urothelial layers (especially apical surface of superficial cells) and increased
bladder CXCR4 expression; 2) increased urine MIF with decreased bladder MIF; 3) increased bladder SDF-1; 4) increased
CXCR4-MIF associations.
Conclusions: These data demonstrate CXCR4-MIF associations occur in vivo in rat bladder and increase in experimental
cystitis. Thus, CXCR4 represents an alternative pathway for MIF-mediated signal transduction during bladder inflammation.
In the bladder, MIF may compete with SDF-1 (cognate ligand) to activate signal transduction mediated by CXCR4.
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Introduction
Macrophage migration inhibitory factor (MIF) is an ubiquitous
pleiotropic cytokine involved in cell proliferation and inflamma-
tion [1,2]. MIF plays an important and unique role in
inflammation since MIF stands upstream of other pro-inflamma-
tory mediators and it can counter-regulate the anti-inflammatory
effects of glucocorticoids [2]. MIF is implicated in animal models
of inflammatory diseases, including arthritis, glomerulonephritis,
acute lung injury and sepsis (for recent review [3]).
Our recent experimental evidence indicates that MIF partici-
pates in bladder inflammation since: (1) MIF is constitutively
expressed in the urothelium [4,5]; (2) bladder MIF expression is
upregulated in different models of experimental cystitis in animals
[6,7]; (3) MIF is released from the bladder during experimental
cystitis [6,8,9] and urinary tract infections in humans [10] and
finally, (4) neutralizing MIF with intravesical antibodies decreased
experimental bladder inflammation [7]. Thus, based on our
experimental observations, our hypothesis of a pro-inflammatory
role for MIF during bladder inflammation agrees well with MIF’s
pro-inflammatory role in several disease models (e.g. arthritis,
Crohn’s disease) where treatment with neutralizing MIF antibod-
ies results in decreased inflammation [11,12].
The mechanism for MIF’s action is not completely defined and
remains an active area of investigation. MIF may exert autocrine
effects through binding to intracellular JAB1 [13] and also
paracrine effects by binding to cell-surface receptors [14]. Until
recently, complex formation between MIF and cell-surface CD74
was the only described mechanism for MIF-receptor interaction
[15] . CD74 is part of the major histocompatibility class-II (MHC-
II) complex; however, a small amount of CD74 can be found on
the cell-surface not associated with MHC-II [16]. MIF binds to
cell-surface CD74 [15] and the MIF-CD74 complex then activates
signal transduction by binding to another cell-surface receptor,
CD44 [14]. We showed that MIF, CD44 and CD74 are all
upregulated in the urothelium after experimental inflammation in
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3898rats [6,17]. Therefore, all of the components are in place during
bladder inflammation for MIF-activated signal transduction to
occur.
Recently, however, a novel functional association between MIF
and chemokine receptors CXCR2 and CXCR4 was described in
T cells in vitro [18]. Chemokines are small proteins that direct
leukocyte traffic to sites of inflammation or injury [19]. CXCR4 is
a G-protein coupled receptor for stromal cell-derived factor-1
(SDF-1/CXCL12). Although chemokines typically display a high
degree of receptor promiscuity, CXCR4 was (until recently)
thought to bind only to SDF-1 [19]. MIF, however, competed with
the recognized ligand for CXCR4 (SDF-1/CXCL12) for binding
to CXCR4 [18].
CXCR4 is expressed by normal urothelium and may be
associated with bladder cancer [20,21]. Therefore, we hypothe-
sized that CXCR4-MIF complex formation may also occur in the
bladder (as described occurring in vitro [18]). Such associations, if
present, would indicate another possible receptor target for MIF
during cystitis, aside from the already described MIF-CD74
association [15].
The object of the present study was to determine if there was an
association between MIF and CXCR4 receptors in the bladder.
Therefore, we examined: 1) location of cytokine receptor CXCR4
in the rat bladder; 2) baseline bladder levels of SDF-1 (cognate
ligand for CXCR4) and changes in response to a chemically-
induced (cyclophosphamide; CYP) model of bladder inflamma-
tion; 3) CXCR4 expression changes after CYP-induced cystitis
and 4) association between CXCR4 and MIF in the bladder
before and after CYP-induced cystitis.
Our results show that both CXCR4 and SDF-1 are constitu-
tively expressed in normal rat bladder and upregulated during
CYP-induced cystitis. Using dual immunohistochemistry we show
that MIF and CXCR4 are colocalized within the same cells in the
urothelium and co-immunoprecipitation studies demonstrate
MIF-CXCR4 associations in the bladder. These MIF-CXCR4
associations are increased during CYP-induced cystitis.
Results
Cyclophosphamide-induced bladder inflammation
Repeated measures ANOVA showed differences between
saline- and CYP-treated rats in body weight, with significant
decreases observed in CYP-treated rats as early as day 3 and
continuing throughout the experiment (day 8; Table 1) but
remaining below a 10% weight-loss threshold established as a
protocol endpoint.
In agreement with our previous findings in male Sprague-
Dawley rats [6] , multiple CYP injections (40 mg/kg every third
day for 8 days, a lower dose than reported effective for female
Wistar rats; 75 mg/kg [22]) induced bladder inflammation.
Hemorrhagic cystitis, however, was not observed in any of the
CYP treated rats. Gross examination of the bladder under the
dissecting microscope revealed lesions on the ventral luminal
surface in all CYP-treated rats, but none of the saline-treated rats.
H&E sections from saline treated rats showed normal bladder
morphology (Figure 1A;B). CYP-treated rats, on the other hand,
showed clear signs of inflammation, including, submucosal edema,
disruption of urothelium, cellular infiltrates, hemorrhage and
fibroblast proliferation (Figure 1C). While the urothelium in saline-
treated rats showed the typical three-layer appearance (Fig 1B),
CYP-treated rats showed hyperplasia (Fig. 1D).
Compared to saline treatment, CYP treatment increased urinary
MIF levels (as measured by ELISA; Figure 1E; 22.262.8 vs.
57.3620.5 in saline vs CYP, respectively; p,0.0464) while
decreasing bladder MIF levels (Fig 1F; 244.1639.7 vs
136.0638.1 ng MIF/mg protein in saline vs CYP treatment
respectively; p=.002), confirming our recent observations [6].
Circulating MIF represents a considerable source of MIF [9] and
presents a possible confound when examining organ levels of MIF.
The MIF ELISA developed in this study was not able to detect
serum MIF. Therefore, our present results represent changes in
tissue levels (or release) of MIF without the confounding presence of
blood/serum MIF in the bladder or urine.
CXCR4 immunostaining in urothelium: co-localization
with MIF and effect of treatment with cyclophosphamide
Using standard immunoperoxidase protocols, moderate to
strong CXCR4 immunostaining was observed in the urothelium
of saline-treated rats, located in basal and intermediate layers, but
not in superficial cells (Fig 2A,B). Following CYP-treatment,
however, there was focal redistribution of CXCR4 immunostain-
ing with superficial cells (and especially at their apical ends)
showing moderate patchy staining (Fig 2C,D), while basal and
intermediate cells appear to decrease in staining intensity. Overall
urothelial staining intensity scores (as rated by blind observer)
showed that cyclophosphamide-treated rats had a lower median
score (1+0.75) compared to saline-treated rats (3+1; p=.0172;
Wilcoxon rank sum test). Computerized analysis of immunostain-
ing intensity showed that basal and intermediate cell staining
decreased after CYP treatment (saline=127.4+8.57; cyclophos-
phamide=77.2+12.08; p=0.0011), thus confirming redistribution
of CXCR4 immunostaining.
We examined the co-localization of CXCR4 and MIF in the
urothelium using dual-immunofluorescence. Figure 3 shows
representative bladder sections from each group immunostained
for MIF (FITC color), CXCR4 (TRITC color) and an overlay of
those two panels (co-localization indicated by orange color;
nuclear staining by DAPI shown in blue). In saline-treated rats,
both MIF and CXCR4 could be localized in the basal and
intermediate layers of the urothelium (but not in superficial cells)
(Fig 4A–C). After CYP-treatment, MIF and CXCR4 are readily
localized throughout the urothelium (Fig 4D–I), even on
superficial cells previously devoid of MIF or CXCR4 (arrows in
Fig 4F,I).
Cyclosphosphamide increased bladder SDF-1 levels
We measured bladder levels of SDF-1, the cognate ligand for
CXCR4, using ELISA. There was a significant difference between
saline (4.461.0) and CYP-treated bladders (7.660.7 ng SDF-1/
mg protein; p,0.05) in the levels of SDF-1. Spleen and skin were
assayed as positive controls and showed the amount of SDF-1 in
spleen is comparable to that found in the bladder (7.94 ng SDF-1/
mg protein). Skin, on the other hand, had greater amounts of
SDF-1 (16.04 ng SDF-1/mg protein) corresponding to approxi-
mately four and two times the amount of SDF-1 in saline and
CYP-treated bladders, respectively.
Table 1. Effect of cyclophosphamide on body weight (g)
Treatment Day 0 Day 3 Day 6 Day 8
Saline (N=10) 32162.6 g 32262.8 32663.5 32663.6
CYP (N=10) 32063.6 30362.5*** 30063.0*** 29563.0***
Mean6S.E.M. Comparisons were made between Saline and CYP groups at each




PLoS ONE | www.plosone.org 2 December 2008 | Volume 3 | Issue 12 | e3898Figure 1. Effect of cyclophosphamide (CYP) treatment on bladder histology, bladder and urine MIF levels. Bladder paraffin sections
stained with H&E showed normal morphology, as represented in A,B. CYP treatment however, caused significant edema and chronic inflammation
(C,D), and some bladders had acute inflammatory cells. Asterisks in C,D mark areas of edema and high numbers of cellular infiltrates. Urothelial
hyperplasia was also observed. In addition, urinary MIF levels were increased by CYP treatment (E; *=p,0.05), while bladder MIF levels were
increased by CYP treatment (F; **=p,0.01). Calibration bar: 1A,1C=500 mm; 1B,1D=100 mm.
doi:10.1371/journal.pone.0003898.g001
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keratinocytes and in endothelial cells in skin blood vessels (Fig 4A)
as has been reported before [23]. However, SDF-1 immunostain-
ing was not detected in bladder (Fig. 4C) or spleen (not shown).
Cyclophosphamide upregulated bladder CXCR4
expression: MIF-CXCR4 associations in the bladder
Real-time PCR showed that CXCR4 mRNA was significantly
upregulated in the bladder following CYP treatment (Figure 5A; <
9-fold increase) when compared to saline. Western-blotting, on the
other hand, showed equivalent levels of CXCR4 protein in the
bladders of saline treated versus CYP-treated rats (Figure 5B).
Co-immunoprecipitation studies with CXCR4 antisera to ‘‘pull-
down’’ CXCR4 protein complexes in bladder homogenates were
followed by MIF Western-blotting in order to detect CXCR4-MIF
complexes in bladder homogenates. Figure 5C shows a represen-
tative experiment where MIF western-blotting of fractions from
bladders of saline and CYP-treated rats were collected from the
CXCR4 antibody column. ‘‘Flow through’’ refers to fractions that
did not adhere to the CXCR4 antibody column (and thus do not
contain CXCR4-complexes), whereas ‘‘Anti-CXCR4’’ refers to
fractions elutedfrom the CXCR4 antibodycolumn(thus containing
CXCR4 complexes). Note that most of the bladder MIF did not
stick to the CXCR4 antibody column (‘‘Flow-through’’) and is not
associated with CXCR4. However, a small amount was found co-
immunoprecipitated with CXCR4 in the saline-treated rats and
these CXCR4-MIF complexes increased after CYP treatment.
Densitometric analysis showed an increase of 3.5 fold in CXCR4-
MIF complexes in CYP treated rats compared to saline controls.
Discussion
The results from the present study demonstrate that CXCR4, a
chemokine cell-surface receptor, is constitutively expressed in
normal rat urothelium localized to basal and intermediate cells.
CYP treatment (aside from producing bladder inflammation and
urothelial hyperplasia, well-described effects of cyclophosphamide
in the bladder [24,25]) also resulted in up-regulation of bladder
CXCR4 mRNA and redistribution of CXCR4 to the entire
urothelial area (including apical area of superficial cells previously
devoid of CXCR4; Fig. 2D). Our findings of apical CXCR4
staining in superficial urothelial cells are in agreement with
observations in colonic epithelial cells [26].
CYP treatment although producing CXCR4 mRNA upregula-
tion (a novel finding) did not result in increased CXCR4 protein
levels, and scoring of CXCR4 immunostaining actually showed a
decrease in staining intensity following CYP treatment. A similar
discrepancy between CXCR4 mRNA expression and protein
levels has been reported in the rat neurons and shown to reflect
activation, increased internalization and degradation of CXCR4
receptors [27] . Such activation, internalization and degradation of
CXCR4 receptors may also account for the patchy CXCR4
immunostaining in the urothelium (especially with immunostain-
ing in the apical surface of superficial cells) and may represent
focal areas of CYP-induced CXCR4 response.
CXCR4 mRNA expression in normal human urothelium,
bladder cancer and also bladder cancer cell lines (J82 and T24)
was previously reported [20] . Addition of SDF-1 (presumably
activating CXCR4 receptors) increased Matrigel invasion and cell
Figure 2. Representative CXCR4 immunostaining in urothelium of saline-treated (A;B) and CYP-treated (C,D) rats. Moderate to strong
CXCR4 immunostaining was seen in basal and intermediate cells in the urothelium of saline treated rats (A;B), with little or no staining in superficial
cells (B; arrows). In CYP-treated rats, there is a significant redistribution of CXCR4 immunostaining with decreased basal and intermediate cell staining
(C;D) while superficial cells appeared stained and moderate staining in apical areas (D; arrowheads). Calibration bar: 2A,2C=200 mm; 2B;2D=50 mm.
doi:10.1371/journal.pone.0003898.g002
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these particular urothelial cancer cells [20]. However, other
investigators using a different bladder cell line (RT-4) did report an
increase in intracellular calcium upon stimulation with SDF-1 [21].
Taken together these results suggest that CXCR4 receptors are
functional in the urothelium. There is also evidence of CXCR4
mRNA expression in other areas of the human urogenital system
(e.g. urethra, cervix) [28].
We examined protein levels of SDF-1 in the bladders of both
saline-treated and CYP-treated rats using ELISA. We report
constitutive levels of SDF-1 in saline-treated bladders which
increase after CYP treatment. Although SDF-1 immunofluores-
cence was readily detectable in skin keratinocytes, we were
unsuccessful in detecting SDF-1 by immunohistochemistry in the
bladder (or the spleen). Since the levels of SDF-1 in the skin
(measured by ELISA) are approximately twice the levels found in
bladder or spleen, we consider it likely that the levels in these
organs were below the detection level for immunohistochemistry.
Recently, down-regulation of SDF-1 mRNA expression in the
bladder (and other pelvic viscera) was reported afer vaginal
distension [29]. To our knowledge, our findings represent the first
demonstration of SDF-1 protein levels in the bladder. Thus our
findings indicate that bladder injury produced by CYP-treatment
results in mRNA upregulation of the chemokine receptor CXCR4
and increased protein levels of its cognate ligand, SDF-1. In
addition to several cytokines reported upregulated in the bladder
after CYP treatment [30], changes in another chemokine
(CX3CL1) and its receptor (CXC3R1) were described as a result
of cyclophosphamide treatment [22]. Therefore, chemokines (in
addition to cytokines) likely represent important mediators of
bladder injury and possible targets for ameliorating bladder
inflammation.
Until recently, CXCR4 was considered to bind exclusively to
SDF-1 [19]. However, recent in vitro evidence showed that
CXCR4 is also capable of binding MIF [18]. In this study we
confirm these in vitro finding since we demonstrate 1) co-
localization of CXCR4 and MIF in the urothelium, both in saline
treated rats and after CYP treatment; 2) CXCR4-MIF associations
are present in saline-treated bladder and increase after CYP
treatment. Therefore, although, not directly tested in this study,
our results suggest that MIF in the bladder may participate in
bladder inflammation either through binding to CXCR4 in the
urothelium (formerly thought to only bind SDF-1 but recently
shown to also bind MIF [18]) or to CD74 (recognized binding
protein for MIF which is upregulated in bladder inflammation [6])
to activate signal transduction pathways that result in the
production of other inflammatory cytokines. Given that bladder
MIF concentrations are approximately 30-fold greater than
bladder SDF-1 concentrations, it is possible that MIF may be
the primary ligand at the CXCR4 receptor in the urothelium.
Moreover, CYP-treatment induced immunostaining of CXCR4 in
superficial urothelial cells previously devoid of CXCR4 (or MIF)
immunostaining. This raises the possibility that these cells will be
activated by MIF present in the urine and in fact, CYP (present
study) and other inflammatory stimuli [8–10] increase luminal
MIF release. We cannot rule out a contribution of renal or ureteral
MIF release to increased urine MIF levels observed in this study
after CYP-treatment, Yet our current findings of increased urine
Figure 3. Co-localization of CXCR4 and MIF in urothelium. Representative sections from rats treated with saline (A–C) or CYP (D–I) are shown.
The figure shows MIF immunostaining (green immunofluorescence), CXCR4 immunostaining (red immunofluorescence) and an overlay panel
combining both immunostaining and a DAPI nuclear stain. MIF immunostaining is seen in basal and intermediate cells and in fibroblasts in the lamina
propria of saline treated rats (A), while superficial cells do not stain for MIF. Arrows show luminal edge of urothelium. CXCR4 is restricted to basal and
intermediate cells of urothelium (B) and lamina propria is not stained. Overlay of these panels (C) demonstrate co-localization of MIF and CXCR4 as
orange coloring of cells. CYP treatment resulted in superficial cell staining for MIF (D,G) and CXCR4 (E,H) and overlay panels (F,I) demonstrate co-
localization as orange color in urothelial cells. Arrows point to superficial cells showing MIF-CXCR4 co-localization. Calibration bar=50 mm.
doi:10.1371/journal.pone.0003898.g003
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consistent with earlier findings where, in animals with bladders
isolated from the kidneys (thus removing potential renal and
ureteral contributions), we observed similar results [7,9]). Thus,
based on our experimental evidence we consider likely that MIF is
released into the lumen from pre-formed stores in the bladder
during inflammation. Therefore, luminal MIF may contribute to
bladder inflammation through binding to at least these two
urothelial cell-surface receptors and suggests that blocking MIF or
cell-surface receptors associated with MIF may prevent or
ameliorate bladder inflammation.
The exact role of CXCR4 and MIF-CXCR4 associations in the
bladder was not addressed in the present study and remains to be
investigated. However, recent evidence from other models
suggests, at least, two interesting and important possibilities for
the involvement of CXCR4 in bladder inflammation and repair
from injury. First, CXCR4 may be mediating urothelial cell
proliferation and repair. CXCR4 and SDF-1 are also expressed in
human intestinal epithelial cells where recent evidence indicates it
participates in epithelial repair following injury and maintaining
mucosal barrier integrity [31,32]. In this model then, chemokines
and chemokine receptors (and particularly CXCR4/SDF-1) may
represent an autocrine/paracrine loop that helps maintain
mucosal barrier integrity and repair as well as regulating mucosal
pathogenesis (including chronic inflammation as seen inflamma-
Figure 4. SDF-1 immunostaining. A) SDF-1 immunostaining was
observed in keratinocytes (arrows) and endothelial cells in blood vessels
(short arrows) in skin. B) Omission of primary antisera eliminated
immunostaining. C) Bladder sections did not show SDF-1 immuno-
staining. Calibration bar=50 mm.
doi:10.1371/journal.pone.0003898.g004
Figure 5. A) Real-time RT-PCR showed significant upregulation of
bladder CXCR4 by CYP treatment (p=0.004) compared to saline. B)
CXCR4 Western-blotting showed no difference in CXCR4 amounts
between saline and CYP-treated rats. GAPDH was used a loading
control. C) Co-immunoprecipitation studies showed CXCR4-MIF associ-
ations in the bladder. A representative experiment is shown where MIF
western-blotting of fractions from bladders of saline and CYP-treated
rats were collected from the CXCR4 antibody column. CXCR4 antisera
was used to ‘‘pull-down’’ CXCR4 complexes in bladder homogenates
followed by MIF Western-blotting to detect CXCR4-MIF complexes.
‘‘Flow through’’ refers to fractions that did not adhere to the CXCR4
antibody column (and thus do not contain CXCR4-complexes), whereas
‘‘Anti-CXCR4’’ refers to fractions eluted from the CXCR4 antibody
column (thus containing CXCR4 complexes). Most of the bladder MIF
did not stick to the CXCR4 antibody column (‘‘Flow-through’’) and is not
associated with CXCR4. However, a small amount was found co-
immunoprecipitated with CXCR4 in saline-treated rats and these
CXCR4-MIF complexes increased after CYP treatment (arrow). Densito-
metric analysis showed an increase of 3.5 fold in CXCR4-MIF complexes
in CYP treated rats compared to saline controls.
doi:10.1371/journal.pone.0003898.g005
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results from the present study indicate that MIF, by associating
with CXCR4 receptors in the bladder (presumably urothelial in
origin), may be competing with SDF-1 at CXCR4 receptors to
participate in epithelial repair following injury. Second, CXCR4
activation may mediate pain hypersensitivity in the bladder.
Recent evidence has clearly shown expression of CXCR4 (and
other chemokine receptors) on dorsal root ganglion (DRG)
neurons [34]. In addition, activation of these receptors produced
excitatory effects on DRG neurons and stimulated release of
Substance P [34]. Also, CXCR4 (and other chemokine receptors
and chemokines) expression was reported in DRG neurons
following a rodent model of persistent neuropathy [35,36]. These
receptors were functional since intracellular calcium was increased
following administration of SDF-1 in vitro [35]. Therefore, based
on their findings, these authors suggest that chemokines and
chemokines receptors may be important targets in the treatment of
chronic pain. In CYP-induced cystitis, then, activation of CXCR4
receptors, either by its recognized ligand SDF-1 (upregulated as a
result of CYP) or due to interaction with MIF (also upregulated as
a result of CYP and present in greater quantities than SDF-1) may
in fact be contributing to pain hypersensitivity. A similar
suggestion has already been made for another chemokine,
CX3CL1, and its receptor during CYP-induced cystitis [22].
Our results contribute to such a hypothesis and expand it to a
different chemokine/receptor system.
In summary, the chemokine receptor CXCR4 is constitutively
expressed in rat urothelium (in basal and intermediate cells) while
CYP-induced bladder inflammation resulted in upregulation of
CXCR4 and immunostaining of superficial cells (previously devoid
of CXCR4). Its cognate chemokine ligand, SDF-1 is also
upregulated by CYP-treatment. CXCR4 and MIF are co-localized
in cells in the urothelium and CYP induced co-localization of
CXCR4 and MIF to superficial cells of the urothelium.
Immunoprecipitation demonstrated an association between
CXCR4 and MIF in the bladder. Therefore, our results suggest
that CXCR4, as a receptor for MIF in urothelial cells, may
contribute to MIF-mediated bladder inflammation. Examining the
differences between MIF activation of CXCR4 receptors versus
MIF activation of CD74 receptors then might provide insights into
the actual mechanism for MIF-mediated effects in the bladder and
possibly other sites.
Methods
All experiments were conducted after obtaining full institutional
animal care and use committee approval and conformed to NIH
Guide for animal experimentation. Bladder inflammation was
produced using a recently published protocol whereby a reduced
dose of cyclophosphamide (CYP) is administered to male Sprague-
Dawley rats in order to avoid profound weight loss and mortality [6].
Cyclophosphamide-induced cystitis
Male Sprague-Dawley rats (N=20; 250–300 g; Harlan, IN,
USA) were anesthetized with halothane and received either saline
(vehicle control group; 0.1 ml/100 g body weight; i.p.; N=10) or
cyclophosphamide (CYP; Sigma, St Louis, MO, USA; in saline;
40 mg/kg; 0.1 ml/100 g body weight; i.p.; N=10) every third day
to induce cystitis [6]. Buprenorphine hydrochloride (0.03 mg/kg;
s.c.; Reckitt Benckiser Pharmaceuticals Inc., Richmond, VA,
USA) was also administered to each rat on the day of injection.
Eight days after the first injection, ten rats (5=saline; 5=CYP)
were anesthetized with sodium pentobarbital (60 mg/kg; i.p.;
Ovation Pharmaceuticals, Deerfield, IL, USA) and perfused with
saline followed by 4% paraformaldehyde and the bladders
collected for histology. Alternatively, rats were re-anesthetized
with halothane (N=10; 5=saline; 5=CYP-treated), bladders
were exposed through an abdominal incision and urine collected
(using a syringe with a 32 gauge needle). Bladders were excised
and quickly frozen (280uC) for protein or mRNA extraction and
the rats were euthanatized.
Histology and Immunohistochemistry
Formaldehyde-fixed bladders were cut coronally through the
mid-detrusor region and embedded in paraffin. Paraffin sections
(4 mm) were stained with hematoxylin and eosin or processed for
CXCR4 immunohistochemistry as follows: Slides were deparaffi-
nized and subjected to antigen retrieval using citrate buffer
(pH 6.0; 95uC for 30 min). Endogenous peroxide was blocked by
incubating the slides in 3% H2O2 for 3 min. The section were
exposed to CXCR4 antisera (1:2000; rabbit-polyclonal; Sigma;
#C3116) overnight at 4uC and then processed using a standard
ABC reaction according to the manufacturer’s protocol (IHC
Select; Chemicon, Temecula, CA, USA). Sections were lightly
counterstained with hematoxylin, coverslipped and examined
using a Leica inverted microscope. Immunostaining intensity was
rated by a pathologist (KAI) blind to experimental conditions from
0 (no staining) to 4 (strong immunostaining). In addition, digital
images were analyzed for CXCR4 immunostaning intensity using
Image J (NIH; Bethesda, MD) and proprietary custom written
plug-ins (University of Colorado-Denver; Prostate Diagnostic
Laboratories, Denver, Aurora).
Frozen (coronal) bladder sections (12 mm) of mid-detrusor were
exposed simultaneously to both MIF (1:200; goat-polyclonal;
Novus Biological, Littleton, CO, USA; #NB100-1789) and
CXCR4 antisera (1:200; rabbit-polyclonal; Sigma; #C3116).
The ability of this MIF antibody to recognize MIF was verified
by preliminary western-blots using rat recombinant MIF (gift from
Torrey Pines) and rat tissue homogenates (data not shown).
Primary antisera were visualized using appropriate secondary
antisera conjugated to fluorescein isothiocyanate (FITC; Jackson
Immunochemicals; West Grove, PA, USA; #705-095-147) or
tetramethylrhodamine isothiocyanate (TRITC; Jackson Immuno-
chemicals; #711-025-152). Sections were coverslipped with fade-
retardant medium (Prolong Gold with DAPI; Invitrogen; Carls-
bad, CA, USA) and examined using a Leica (Leica microsystems,
Wetzlar, Germany) inverted microscope, equipped with a Leica
digital camera. Overlay pictures showing MIF (green; FITC),
CXCR4 (red; TRITC) and DAPI nuclear counterstaining were
obtained with Leica software. Control sections included omission
of either or both primariy antisera, or omission of either or both
secondary antisera.
For SDF-1 immunohistochemistry, frozen bladder sections were
exposed to SDF-1 antisera (rabbit polyclonal; Torrey Pines
Biolabs, Houston, TX, USA; TP201;1:200; overnight 4uC) and
visualized with TRITC. Spleen and skin sections were used as
positive controls.
MIF and SDF-1 ELISA
Urine and bladders from saline and CYP-treated rats were
assayed for levels of MIF and SDF-1 (bladders only) using enzyme-
linked immunoabsorbent assay (ELISA). MIF ELISA was also
tested for its ability to detect serum MIF. Briefly, high binding
ELISA plates (Microlite 2, ThermoScientific, Waltham, MA,
USA) were coated with 100 ml of primary antibody (1 mg/ml; anti-
MIF; Abcam; Cambridge, MA, USA; #ab7207 or anti-SDF-1;
Torrey Pines Biolabs; TP201) at room temperature overnight. The
ability of this MIF antibody to recognize MIF was verified by
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Torrey Pines) and rat tissue homogenates (data not shown). Plates
were blocked with 200 ml reagent diluent (1% BSA in PBS pH 7.4)
for 1 h at room temperature. Recombinant rat MIF (a gift from
Torrey Pines) or recombinant SDF-1 (Preprotech Inc; Rocky Hill,
NJ, USA) was used to generate a standard curve from 1.6 to
100 ng/ml in reagent diluent. Samples were diluted to the
appropriate concentration in reagent diluent and applied in
duplicate wells. Plates were covered with adhesive tape and
incubated 2 h at room temperature. Individual wells were then
washed three times with wash buffer (PBS containing 0.05%
Tween-20, pH 7.4) using an automated plate washer (Thermo-
Scientific). Detection antibody (biotinylated-goat anti-MIF,
BAF289, R&D Systems, Minneapolis, MN, USA or biotinylated
goat anti-SDF-1, R&D Systems) was added at a final concentra-
tion of 200 ng/ml, the plates recovered with adhesive and
incubated 2 h at room temperature. The wells were washed as
described above, 100 ml streptavidin-horseradish peroxidase
(1:200 dilution in reagent diluent, DY998, R&D Systems) added
to each well and the covered plate was incubated for 20 minutes at
room temperature. The wells were washed as described above,
100 ml peroxidase substrate (R&D; DY999) was added and each
well read using a plate reader (Biotek, Winooski, VT, USA). A
standard curve was created using linear regression and sample
concentrations calculated by interpolation (PRISM 4.02, Graph-
Pad Software, La Jolla, CA, USA). Assays had an inter- and intra-
plate coefficient of variation of 15.3% and 18%, respectively for
MIF and 7.2% (both for inter- and intraplate) for SDF-1. Bladder
MIF and SDF-1 levels are expressed normalized to protein
amount (BCA, Thermo Scientific) present in the samples. Urine
creatinine was determined using a commercially available assay
(Exocell, Philadelphia, PA, USA) and performed according to the
manufacturer’s protocol. Urine MIF levels are normalized to urine
creatinine levels in the samples.
Bladder CXCR4 mRNA expression, Western blotting and
CXCR4-MIF co-immunoprecipitation
Total RNA was isolated from bladder tissues using Trizol
(Invitrogen) and CXCR4 (SuperArray primer; PPR06440A;
SABiosciences, Frederick, MD, USA) and 18S rRNA (control;
SuperArray: PPR57734E) gene expression was determined by
Real-time RT-PCR (Opticon, Bio-Rad, Hercula, CA, USA) using
SYBR Green incorporation and the DDCT method of analysis.
Differences in bladder CXCR4 mRNA expression between saline-
treated and cyclosphamide-treated rats were determined using a
Student’s t-test. p,0.05 was considered significant.
Western-blotting of bladder homogenates was performed under
non-reducing conditions following the manufacturer’s protocols
(NuPAGE Bis-Tris gels, Invitrogen) as described previously [8].
Briefly, 20 ml of bladder homogenates were loaded onto NuPAGE
Bis-Tris gels (4–12%; Invitrogen). After electrophoresis, separated
proteins were transferred to a polyvinylidene fluoride membrane.
CXCR4 protein bands were detected using a polyclonal antibody
to CXCR4 (Sigma; C3116) and chemiluminescent substrate
(Sigma 1:1000). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as a loading control. Band intensities were
quantified using Kodak Image Station (Kodak, Rochester, NY,
USA) and expressed as a ratio of the saline group.
In order to detect MIF binding to CXCR4 in the bladder, we
used CXCR4 co-immunoprecipitation followed by MIF western
blotting. CXCR4 was precipitated from frozen bladder tissue
homogenates (200 mg of total protein) using CXCR4 antibody
(5 mg, Sigma; #C3116). CXCR4 containing protein complexes
were isolated using Protein G agarose beads and then separated by
denaturing, reducing SDS electrophoresis. MIF containing bands
were identified by Western blotting using biotinylated anti-MIF
antibody (1:1000 dilution, R&D Systems).
Statistical Analysis
Generally, data are presented as Mean6S.E.M and group
differences were determined with t-tests. Visual scoring of CXCR4
immunostaining is presented as Median6Interquartile range and
differences between the two groups were assessed using a
Wilcoxon rank sum test, whereas digitized CXCR4 immunostain-
ing are presented as Mean6S.E.M of arbitrary intensity scores
and differerences are analyzed using t-tests. Body weight loss as a
function of cyclophosphamide treatment was tested using two-way
(Treatment x Time) repeated-measures analysis of variance
(ANOVA). Bonferroni post-hoc t-tests examined body weight
differences between saline and cyclophosphamide groups at
specific time points.. Analyses were conducted using statistical
software (R; http://www.r-project.org/).
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